Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Cost Reimbursement
Drugs
Locations
Clinical Specialty
641-660 of 991 trials

Mindfulness Training and Oxytocin for Stress Relief

We are studying whether combining oxytocin treatment with mindfulness training can better reduce stress in adults with high stress levels. This trial will measure changes in psychological distress and other related factors.

Psychological Distress≤3 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost Reimbursement

Polymyalgia Rheumatica: Rituximab Study

We are investigating whether rituximab can help reduce the need for corticosteroids in people with relapsing polymyalgia rheumatica. This study compares rituximab to a placebo to assess its effectiveness.

Polymyalgia Rheumatica1-2 yearsMonitoring phase (IV)6-10 visitsStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyRheumatology

YTB323 for Treatment-Resistant Generalized Myasthenia Gravis

We are studying the safety and effects of YTB323 in patients with treatment-resistant generalized myasthenia gravis. This research aims to understand how the drug works in the body and its potential to improve symptoms.

Myasthenia Gravis1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementInternal MedicineNeurology

Pulmonary Arterial Hypertension: LTP001 Treatment Study

We are studying a new treatment called LTP001 in healthy adults and in individuals with pulmonary arterial hypertension. The goal is to evaluate its safety and how well it may improve exercise capacity and overall health.

Pulmonary Arterial HypertensionSafety phase (I)Efficacy phase (II)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyPulmonology

Advanced Lung Cancer: Eftilagimod Alfa with Pembrolizumab

We are studying a new drug, eftilagimod alfa, combined with pembrolizumab and chemotherapy for patients with advanced non-small cell lung cancer. The goal is to see if this combination works better than standard treatments.

Advanced Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)Investigational MedicinesCost ReimbursementPartially RemoteOncology

Lung Cancer Treatment: Nivolumab + Relatlimab with Chemotherapy

We are studying if a new combination treatment helps people with advanced non-small cell lung cancer live longer compared to standard treatment. This trial is for those whose cancer has spread or returned after previous treatment.

Advanced Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Intrahepatic Cholangiocarcinoma: PUMP IV Trial

We are studying a new chemotherapy method to help prevent liver cancer from coming back after surgery. This trial will also look at side effects and how it affects patients' quality of life.

Intrahepatic Cholangiocarcinoma3-6 monthsEfficacy phase (II)6-10 visitsCost ReimbursementGastroenterologyHepatologyOncology

IDH1/IDH2-Mutant Glioma: Vorasidenib with Temozolomide

We are studying the safety and effectiveness of a new drug, vorasidenib, combined with temozolomide for patients with IDH1- or IDH2-mutant gliomas. This research aims to see if this combination can improve treatment outcomes.

IDH1-mutant GliomaIDH2-mutant Glioma>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Sickle Cell Disease: Hydroxycarbamide Tablets for Children

We are studying the effects of a twice-daily dose of Hydroxycarbamide in children with sickle cell disease. This trial aims to evaluate its safety, effectiveness, and how well children tolerate the treatment.

Sickle Cell Disease>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyPediatrics

Cystic Fibrosis: VX-121/Tezacaftor/Deutivacaftor Therapy

We are studying a new combination therapy for children with cystic fibrosis to evaluate its safety and how well it works. This trial focuses on kids aged 1 to 11 years.

Cystic Fibrosis6-12 monthsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementInternal MedicinePulmonology

Giant Cell Arteritis and Polymyalgia Rheumatica: Hydrocortisone Study

We are investigating whether hydrocortisone can help patients with GCA and PMR who report symptoms of adrenal insufficiency after stopping glucocorticoids. This study aims to provide better treatment options for these patients.

Tertiary Adrenal Insufficiency>2 yearsMonitoring phase (IV)≤5 visitsStandard MedicinesCost ReimbursementPartially RemoteEndocrinologyRheumatology

Efgartigimod for Children with Generalized Myasthenia Gravis

We are studying a new treatment for children aged 2 to under 18 with generalized myasthenia gravis. The trial will evaluate the safety, dosing, and effects of this treatment on their daily lives.

Myasthenia Gravis6-12 monthsEfficacy phase (II)Confirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementInternal MedicineNeurology

Chronic Rhinosinusitis with Nasal Polyps: Tezepelumab Study

We are investigating how tezepelumab affects symptoms in adults with chronic rhinosinusitis and nasal polyps. The study looks at changes in nasal congestion, sense of smell, and overall quality of life.

Chronic Rhinosinusitis with Nasal Polyps3-6 monthsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOtolaryngologyPulmonology

Hypertrophic Cardiomyopathy: Sotagliflozin Study

We are investigating whether sotagliflozin can improve symptoms in people with hypertrophic cardiomyopathy. The study also looks at the safety of this treatment compared to a placebo.

Hypertrophic Cardiomyopathy6-12 monthsConfirmation phase (III)6-10 visitsInvestigational MedicinesCost ReimbursementCardiologyInternal Medicine

Cluster Headache Study: Understanding Brain Activity

We are exploring how brain activity and receptor availability differ in people with cluster headaches during active and inactive periods. This research may help us learn more about the condition and its effects on the brain.

Nervous System Diseases>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementNeurology

Pancreatic Cancer: TCR-Modified T-Cell Therapy

We are studying a new therapy using modified T-cells for adults with advanced pancreatic cancer that has specific genetic mutations. The trial aims to assess safety and how well this treatment may work.

Pancreatic Cancer>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Opioid Dependency Treatment: Suboxone vs. Methadone

We are comparing the effectiveness of Suboxone and methadone in reducing opioid misuse for patients with chronic pain. The study also looks at how these treatments affect pain relief, well-being, and cognitive function.

Opioid Use Disorder>2 yearsMonitoring phase (IV)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementInternal MedicinePsychiatry

Flu Vaccine Study: LAIV in Young Children

We are studying how the LAIV flu vaccine affects the immune response in young children. This research aims to see how well it protects against flu and influences overall health.

Influenza≤3 monthsMonitoring phase (IV)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPediatricsPulmonology

HIV Treatment: IMC-M113V Study

We are evaluating a new treatment, IMC-M113V, for people with chronic HIV infection who are already on medication. The study will help us understand its safety and how it affects the immune system.

Chronic HIV Infection3-6 monthsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementInfectious DiseasesInternal Medicine

Semaglutide for Obesity and Resistant Hypertension

We are exploring whether semaglutide can help people with obesity and resistant hypertension better control their blood pressure compared to a placebo. This study aims to assess if this approach is feasible.

Resistant HypertensionObesity6-12 monthsConfirmation phase (III)Standard MedicinesCost ReimbursementPartially RemoteCardiologyEndocrinologyInternal Medicine